Results · Apr-Jun 2026
Shree Ganesh Biotech (India) Q1 FY27 results
Sales grew 3% to ₹1.4 crore from ₹1.4 crore in Apr-Jun 2025.
Operating profit was −₹0.89 crore, an operating margin of −62.5% (down 56.1 points from a year ago).
Net profit turned into a loss of ₹0.57 crore, from a profit of ₹0.33 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −33%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1.4 | 1.4 | +3% |
| Operating profit (EBITDA) | -0.9 | -0.1 | n/m |
| Operating margin | −62.5% | −6.4% | −56.1 pts |
| Net profit | -0.6 | 0.3 | swings to a loss |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.